TAG-72 Antibody (6A191): sc-73109

TAG-72 Antibody (6A191) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) with broad species reactivity through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein primarily localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for various cancers. TAG-72 expression is notably high in approximately 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues, which underscores TAG-72′s potential as a diagnostic and therapeutic target. TAG-72 is also significantly expressed in low-grade mucoepidermoid carcinomas, yet absent in pure squamous cell mucoepidermoid carcinomas, highlighting TAG-72′s specificity in cancer detection. Furthermore, TAG-72 is associated with several gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas, and TAG-72 expression in human prostatic adenocarcinomas has been shown to negatively correlate with the Gleason grade of differentiation, indicating TAG-72′s relevance in tumor aggressiveness. Additionally, TAG-72 is expressed in the majority of gastric, esophageal, pancreatic, and non-small cell lung carcinomas, making TAG-72 a valuable biomarker for a wide range of malignancies. Anti-TAG-72 antibody (6A191) is particularly useful for purifying primary ovarian cancer cells from patient ascites, facilitating further research and potential therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (6A191) References:

1. p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system.  |  Kanthan, R., et al. 2000. Arch Pathol Lab Med. 124: 234-9. PMID: 10656732
2. Serum levels of TAG 72 and CA 15.3 in patients with gynaecological neoplasms.  |  Correale, M., et al. 1992. Eur J Gynaecol Oncol. 13: 82-4. PMID: 1511720
3. Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols.  |  Ferroni, P., et al. 1990. Int J Biol Markers. 5: 166-76. PMID: 2093732
4. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.  |  Tempero, M., et al. 1989. Am J Surg Pathol. 13 Suppl 1: 89-95. PMID: 2699170
5. Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas.  |  Stanick, D., et al. 1988. Cancer Invest. 6: 279-87. PMID: 3048576
6. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.  |  Murray, JL., et al. 1995. Cancer Res. 55: 5925s-5928s. PMID: 7493372
7. TAG-72 expression in lymph nodes and RIGS.  |  Hitchcock, CL., et al. 1996. Dis Colon Rectum. 39: 473-5. PMID: 8878513
8. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.  |  Blanco, I., et al. 1997. J Clin Immunol. 17: 96-106. PMID: 9049790
9. Development of a human IgA antibody specific for the tumour antigen TAG-72.  |  Ingram, PE., et al. 1997. Biochem Soc Trans. 25: 330S. PMID: 9191375
10. Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma.  |  Gonzalez, A., et al. 1997. Int J Biol Markers. 12: 112-7. PMID: 9479593

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.